These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16931226)

  • 21. Recurrent renal hyperparathyroidism due to parathyromatosis.
    Vulpio C; D'Errico G; Mattoli MV; Bossola M; Lodoli C; Fadda G; Bruno I; Giordano A; Castagneto M
    NDT Plus; 2011 Oct; 4(5):318-20. PubMed ID: 25984178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent renal secondary hyperparathyroidism caused by supernumerary mediastinal parathyroid gland and parathyromatosis: A case report.
    Li L; He C; Cheng G; Cao J; Wang C; Tang Y; Zhang W
    Front Surg; 2023; 10():1135596. PubMed ID: 37021088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of hypercalcemia with ibandronate in case of acute renal failure].
    Bergner R; Henrich DM; Hoffmann M; Bruckner D; Uppenkamp M
    Internist (Berl); 2006 Mar; 47(3):293-6. PubMed ID: 16470360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent hyperparathyroidism caused by benign neoplastic seeding: two cases of parathyromatosis and a review of the literature.
    Twigt BA; van Dalen T; Vroonhoven TJ; Consten EC
    Acta Chir Belg; 2013; 113(3):228-32. PubMed ID: 24941723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent hyperparathyroidism and forearm parathyromatosis after total parathyroidectomy.
    Melck AL; Carty SE; Seethala RR; Armstrong MJ; Stang MT; Ogilvie JB; Yip L
    Surgery; 2010 Oct; 148(4):867-73; discussion 873-5. PubMed ID: 20800255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S; Tisell LE; Lindstedt G; Lundberg PA
    Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraoperative sestamibi scanning in reoperative parathyroidectomy.
    Rossi HL; Ali A; Prinz RA
    Surgery; 2000 Oct; 128(4):744-50. PubMed ID: 11015110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hypercalcemic crisis due to primary hyperparathyroidism].
    Guthoff M; Georges G; Wehrmann M; Teichmann R; Gröne E; Risler T; Häring HU; Müssig K
    Dtsch Med Wochenschr; 2008 Dec; 133(50):2639-43. PubMed ID: 19052999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised clinical study of alfacalcidol and paricalcitol.
    Hansen D
    Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parathyromatosis as a cause of recurrence primary hyperparathyroidism: A case report.
    Ilyicheva EA; Bersenev GA
    Int J Surg Case Rep; 2021 Mar; 80():105689. PubMed ID: 33752295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parathyromatosis as cause of recurrent secondary hyperparathyroidism: a cytologic diagnosis.
    Baloch ZW; Fraker D; LiVolsi VA
    Diagn Cytopathol; 2001 Dec; 25(6):403-5. PubMed ID: 11747238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcific uremic arteriolopathy treated with cinacalcet, paricalcitol, and autologous growth factors.
    Kakagia D; Kriki P; Thodis E; Roumeliotis A; Vargemezis V
    J Cutan Med Surg; 2011; 15(2):121-4. PubMed ID: 21477562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Parathyroid carcinoma. Therapeutic strategies derived from 20 years of experience].
    Pelizzo MR; Piotto A; Bergamasco A; Rubello D; Casara D
    Minerva Endocrinol; 2001 Mar; 26(1):23-9. PubMed ID: 11323564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pericardial Type 1 Parathyromatosis: A very rare cause of primary hyperparathyroidism.
    Altin O; Sari R
    Acta Endocrinol (Buchar); 2020; 16(4):505-507. PubMed ID: 34084244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tuberculosis complicating tertiary hyperparathyroidism in a patient with end-stage renal disease: a case report.
    Sadideen HM; Blaker P; O'Donnell P; Taylor J; Goldsmith DJ
    J Nephrol; 2008; 21(3):438-41. PubMed ID: 18587734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis.
    Drüeke TB; McCarron DA
    N Engl J Med; 2003 Jul; 349(5):496-9. PubMed ID: 12890849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.